Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
Sung Yong Lee, Chang‐Min Choi, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong‐Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Ji Young Park, Young‐Chul Kim, In‐Jae Oh, Chi Young Jung, Sang Hoon Lee, Seong Hoon Yoon, Juwhan Choi, Tae Won Jang
Abstract
BACKGROUND: ) non-small cell lung cancer (NSCLC) in a real-world setting. METHODS: mutation category. RESULTS: 40.3 months, P=0.0117). Median OS was 30.5/37.7 months in patients receiving chemotherapy/osimertinib as subsequent therapy. The most common treatment-related adverse events (TRAEs; any grade/grade ≥3) were diarrhea (31.3%/8.5%) and rash (23.0%/8.1%). Overall, 34 patients (8.1%) discontinued afatinib due to AEs. CONCLUSIONS: mutations. AE management with dose reductions facilitated a long TTD, prolonging the chemotherapy-free period for many patients.